Cancer and rare genetic disease focused group Agios Pharmaceuticals has appointed Jackie Fouse to its board of directors as the company prepares to launch its first precision medicine.
She said: “The execution across Agios’ research and clinical development programmes is remarkable, and I’m pleased to be joining the board during this exciting time.
“I look forward to working with the Agios team.”
Fouse’s career saw her join Celgene in 2010 as its chief financial officer and she most recently served as its president and chief operating officer until earlier this year.
Prior to her tenure at Celgene, Fouse worked for Alcon Laboratories, an ophthalmic pharmaceutical and medical device company.
David Schenkein, chief executive officer at Agios, said: “Through her tenure at Celgene we had the privilege of working with Jackie and seeing first hand the value she brings to a growing biotechnology company, so we are thrilled to welcome her to the Agios board of directors.”